We fight for human health.

CureVac is the first company to successfully harness messenger RNA (mRNA) for medical purposes. The principle is promising: use natural mRNA as a data carrier to instruct the human body to produce its own proteins to fight a wide range of diseases.

News

CureVac to Present at the 19th Annual Piper Jaffray Healthcare Conference in New York

Press Release of November 21, 2018

Read more

University of Tübingen Names CureVac Co-Founder & Supervisory Board Chairman, Ingmar Hoerr, Honorary Senator

Press Release of November 7, 2018

Read more

CureVac to Present at the 2018 Society for Immunotherapy of Cancer Annual Meeting in Washington, DC

Press Release of November 7, 2018

Read more

CureVac Announces First Study Participant Enrolled in Phase I Clinical Trial Testing Prophylactic mRNA Rabies Vaccine

Press Release of October 23, 2018

Read more
http://www.curevac.com/news/curevac-announces-new-management-structure/

Transition in CureVac's Top Management

Picture: Ingmar Hoerr (left) and Dan Menichella (right)

Read more

CureVac Receives U.S. Patent Covering Entire Process for Pharmaceutical Manufacturing of RNA

Press Release of March 22, 2018

Read more

CureVac to Pursue mRNA Vaccines Against Flu and Malaria - Extends ongoing collaboration with BMGF

Press Release of February 13, 2018

Read more

CureVac Highlights Milestones and Outlook at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco

Press Release of January 10, 2018

Read more

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

Press Release of October 18, 2017

Read more

Work@CureVac

Do you want to fight together with us for human health?

Read more